Analyzing Enovis (ENOV) and Its Rivals

Enovis (NYSE:ENOVGet Rating) is one of 48 public companies in the “Surgical appliances & supplies” industry, but how does it contrast to its competitors? We will compare Enovis to similar businesses based on the strength of its institutional ownership, analyst recommendations, risk, profitability, earnings, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Enovis and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enovis 0 1 0 0 2.00
Enovis Competitors 179 962 2107 71 2.62

Enovis currently has a consensus target price of $67.00, suggesting a potential upside of 21.25%. As a group, “Surgical appliances & supplies” companies have a potential upside of 80.41%. Given Enovis’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Enovis has less favorable growth aspects than its competitors.


This table compares Enovis and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enovis 1.77% 6.35% 3.57%
Enovis Competitors -157.64% -51.27% -13.88%

Valuation & Earnings

This table compares Enovis and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Enovis $3.85 billion $71.66 million 41.86
Enovis Competitors $1.29 billion $145.66 million 32.67

Enovis has higher revenue, but lower earnings than its competitors. Enovis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

50.9% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 8.2% of Enovis shares are held by company insiders. Comparatively, 10.9% of shares of all “Surgical appliances & supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Enovis has a beta of 2.2, meaning that its stock price is 120% more volatile than the S&P 500. Comparatively, Enovis’ competitors have a beta of 0.81, meaning that their average stock price is 19% less volatile than the S&P 500.


Enovis competitors beat Enovis on 7 of the 13 factors compared.

Enovis Company Profile (Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with's FREE daily email newsletter.